Article Text

Download PDFPDF
Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis
  1. T Keersmaekers1,
  2. K Claes1,
  3. D R Kuypers1,
  4. K de Vlam2,
  5. P Verschueren2,
  6. R Westhovens2
  1. 1
    Department of Nephrology, University Hospitals KU Leuven, Leuven, Belgium
  2. 2
    Department of Rheumatology, University Hospitals KU Leuven, Leuven, Belgium
  1. Dr R Westhovens, Department of Rheumatology, University Hospitals KU Leuven, Herestraat 49, B-3000 Leuven, Belgium; rene.westhovens{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Secondary AA-amyloidosis is sometimes associated with chronic inflammatory arthritis, such as rheumatoid arthritis (RA) and spondylarthropathies (SpA), with an extracellular accumulation of amyloid proteins in the tissues of various organs. This amyloid is composed of serum amyloid P-component (SAP), serum amyloid A (SAA), an acute phase protein, and proteoglycans. Renal involvement is the most frequent manifestation of secondary amyloidosis, usually presenting with asymptomatic proteinuria.

According to earlier literature, the prognosis of AA-amyloidosis was considered very poor. Treatment with corticosteroids and immunosuppressive drugs, mainly alkylating agents, consisted of adequate suppression of the underlying inflammatory process. Recently, eprodisate was shown to slow the decline in renal function by inhibition of the production of …

View Full Text


  • Competing interests: Declared. RW and PV are consultants for Schering Plough.